FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896490588> ?p ?o ?g. }

• W2896490588 endingPage "226" @default.
• W2896490588 startingPage "219" @default.
• W2896490588 abstract "Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer, as well as genomic alterations identified and their potential actionability. Of 4864 patients from multiple institutions for whom NGS was ordered by physicians, only 67 (1.4%) had prostate cancer, representing 1/10 the ordering rate for lung cancer. Prostate cancers harbored 148 unique alterations affecting 63 distinct genes. No two patients had an identical molecular portfolio. The median number of characterized genomic alterations per patient was 3 (range, 1 to 9). Fifty-six of 67 patients (84%) had ≥ 1 potentially actionable alteration. TMPRSS2 fusions affected 28.4% of patients. Genomic aberrations were most frequently detected in TP53 (55.2% of patients), PTEN (29.9%), MYC (17.9%), PIK3CA (13.4%), APC (9.0%), BRCA2 (9.0%), CCND1 (9.0%), and RB1 genes (9.0%). The PI3K (52.2% of patients), WNT (13.5%), DNA repair (17.9%), cell cycle (19.4%), and MAPK (14.9%) machinery were commonly impacted. A minority of patients harbored BRAF, NTRK, ERBB2, or mismatch repair gene abnormalities, which are highly druggable in some cancers. Only ~ 10% of prostate cancer trials (clinicaltrials.gov, year 2017) applied a (non-hormone) biomarker before intervention. In conclusion, though use of clinical-grade NGS is relatively low and only a minority of trials deploy DNA-based biomarkers, many prostate cancer-associated molecular alterations may be pharmacologically tractable with genomcially targeted therapy or, in the case of mismatch repair anomalies, with checkpoint inhibitor immunotherapy." @default.
• W2896490588 created "2018-10-26" @default.
• W2896490588 creator A5018352586 @default.
• W2896490588 creator A5053481267 @default.
• W2896490588 creator A5060647012 @default.
• W2896490588 creator A5063735868 @default.
• W2896490588 creator A5077950689 @default.
• W2896490588 date "2018-10-19" @default.
• W2896490588 modified "2023-10-18" @default.
• W2896490588 title "Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing" @default.
• W2896490588 cites W1542766165 @default.
• W2896490588 cites W1578291413 @default.
• W2896490588 cites W1846586690 @default.
• W2896490588 cites W1940241680 @default.
• W2896490588 cites W1960850967 @default.
• W2896490588 cites W2009494242 @default.
• W2896490588 cites W2058657848 @default.
• W2896490588 cites W2071665742 @default.
• W2896490588 cites W2086924064 @default.
• W2896490588 cites W2091888468 @default.
• W2896490588 cites W2103724490 @default.
• W2896490588 cites W2109218597 @default.
• W2896490588 cites W2127250774 @default.
• W2896490588 cites W2160981405 @default.
• W2896490588 cites W2161112598 @default.
• W2896490588 cites W2161375781 @default.
• W2896490588 cites W2167557133 @default.
• W2896490588 cites W2170552969 @default.
• W2896490588 cites W2197170290 @default.
• W2896490588 cites W2200963198 @default.
• W2896490588 cites W2235405584 @default.
• W2896490588 cites W2276287001 @default.
• W2896490588 cites W2296139876 @default.
• W2896490588 cites W2303146341 @default.
• W2896490588 cites W2408112818 @default.
• W2896490588 cites W2412140884 @default.
• W2896490588 cites W2463504723 @default.
• W2896490588 cites W2530935884 @default.
• W2896490588 cites W2546632559 @default.
• W2896490588 cites W2746620505 @default.
• W2896490588 cites W2747774814 @default.
• W2896490588 cites W2790254562 @default.
• W2896490588 doi "https://doi.org/10.1080/15384047.2018.1523849" @default.
• W2896490588 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6343723" @default.
• W2896490588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30339521" @default.
• W2896490588 hasPublicationYear "2018" @default.
• W2896490588 type Work @default.
• W2896490588 sameAs 2896490588 @default.
• W2896490588 citedByCount "27" @default.
• W2896490588 countsByYear W28964905882019 @default.
• W2896490588 countsByYear W28964905882020 @default.
• W2896490588 countsByYear W28964905882021 @default.
• W2896490588 countsByYear W28964905882022 @default.
• W2896490588 countsByYear W28964905882023 @default.
• W2896490588 crossrefType "journal-article" @default.
• W2896490588 hasAuthorship W2896490588A5018352586 @default.
• W2896490588 hasAuthorship W2896490588A5053481267 @default.
• W2896490588 hasAuthorship W2896490588A5060647012 @default.
• W2896490588 hasAuthorship W2896490588A5063735868 @default.
• W2896490588 hasAuthorship W2896490588A5077950689 @default.
• W2896490588 hasBestOaLocation W28964905881 @default.
• W2896490588 hasConcept C121608353 @default.
• W2896490588 hasConcept C126322002 @default.
• W2896490588 hasConcept C143998085 @default.
• W2896490588 hasConcept C190283241 @default.
• W2896490588 hasConcept C2776235491 @default.
• W2896490588 hasConcept C2777609662 @default.
• W2896490588 hasConcept C2778042024 @default.
• W2896490588 hasConcept C2779134260 @default.
• W2896490588 hasConcept C2780192828 @default.
• W2896490588 hasConcept C3008058167 @default.
• W2896490588 hasConcept C502942594 @default.
• W2896490588 hasConcept C524204448 @default.
• W2896490588 hasConcept C54355233 @default.
• W2896490588 hasConcept C60644358 @default.
• W2896490588 hasConcept C71924100 @default.
• W2896490588 hasConcept C86554907 @default.
• W2896490588 hasConcept C86803240 @default.
• W2896490588 hasConceptScore W2896490588C121608353 @default.
• W2896490588 hasConceptScore W2896490588C126322002 @default.
• W2896490588 hasConceptScore W2896490588C143998085 @default.
• W2896490588 hasConceptScore W2896490588C190283241 @default.
• W2896490588 hasConceptScore W2896490588C2776235491 @default.
• W2896490588 hasConceptScore W2896490588C2777609662 @default.
• W2896490588 hasConceptScore W2896490588C2778042024 @default.
• W2896490588 hasConceptScore W2896490588C2779134260 @default.
• W2896490588 hasConceptScore W2896490588C2780192828 @default.
• W2896490588 hasConceptScore W2896490588C3008058167 @default.
• W2896490588 hasConceptScore W2896490588C502942594 @default.
• W2896490588 hasConceptScore W2896490588C524204448 @default.
• W2896490588 hasConceptScore W2896490588C54355233 @default.
• W2896490588 hasConceptScore W2896490588C60644358 @default.
• W2896490588 hasConceptScore W2896490588C71924100 @default.
• W2896490588 hasConceptScore W2896490588C86554907 @default.
• W2896490588 hasConceptScore W2896490588C86803240 @default.
• W2896490588 hasFunder F4320337351 @default.
• W2896490588 hasIssue "2" @default.
• W2896490588 hasLocation W28964905881 @default.

• next